Across TCGA pan-cancer cohorts, RNU6ATAC31P RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated RNU6ATAC31P data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNU6ATAC31P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6ATAC31P expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

LUAD, ESCA, and HNSC are the cancer types where RNU6ATAC31P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.141	0.788	<.001	54	view →
ESCA	OS	Tertile	III,IV	1.000	0.374	.017	36	view →
HNSC	DFS	Tertile	III,IV	0.050	0.611	<.001	36	view →
STAD	OS	Tertile	IV	0.111	0.433	.002	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RNU6ATAC31P tumor-vs-normal RNA expression · all RNU6ATAC31P data types